OligoRARE (EORTC 1945)
Research type
Research Study
Full title
Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial.
IRAS ID
293884
Contact name
Jenny Sherriff
Contact email
Sponsor organisation
EORTC
Clinicaltrials.gov Identifier
Duration of Study in the UK
11 years, 3 months, 14 days
Research summary
This study is looking at the use of a technique called stereotactic body radiation therapy (SBRT) as a treatment for people with rare oligometastatic cancers.
This study aims to find out whether adding SBRT to standard cancer treatment helps to better control this type of cancer from further spreading. Participants will either receive standard treatment or standard treatment plus SBRT. Whilst doctors think adding SBRT may work better against this type of cancer than standard treatment on its own, there is no proof of this yet, which is why this study is being done.
This study will take place in NHS sites in the UK as part of a wider international study. The study is sponsored and coordinated by the EORTC (European Organisation for Research and Treatment of Cancer), a non-profit organisation based in Brussels.
REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
21/EE/0181
Date of REC Opinion
5 Aug 2021
REC opinion
Further Information Favourable Opinion